Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Authors
Keywords
targeted therapy, drug resistance, receptor tyrosine kinases, cancer
Journal
Frontiers of Medicine
Volume 9, Issue 2, Pages 134-138
Publisher
Springer Nature
Online
2015-05-09
DOI
10.1007/s11684-015-0396-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGF promotes mammalian cell growth by suppressing cellular senescence
- (2014) Peter B Alexander et al. CELL RESEARCH
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
- (2014) Chong Sun et al. TRENDS IN BIOCHEMICAL SCIENCES
- RON confers lapatinib resistance in HER2-positive breast cancer cells
- (2013) Quanren Wang et al. CANCER LETTERS
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
- (2013) J. P. Wagner et al. Science Signaling
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
- (2012) Ho-June Lee et al. Cancer Discovery
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
- (2010) Shivanni Kummar et al. NATURE REVIEWS DRUG DISCOVERY
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
- (2008) D. A. Grueneberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started